Edition:
United Kingdom

People: Shin Nippon Biomedical Laboratories Ltd (2395.T)

2395.T on Tokyo Stock Exchange

766JPY
19 Apr 2019
Change (% chg)

¥-18 (-2.30%)
Prev Close
¥784
Open
¥791
Day's High
¥797
Day's Low
¥763
Volume
748,000
Avg. Vol
560,412
52-wk High
¥980
52-wk Low
¥442

Nagata, Ryoichi 

Mr. Ryoichi Nagata was named Chairman of the Board, President, Group Chief Executive Officer and Representative Director in SHIN NIPPON BIOMEDICAL LABORATORIES, LTD., as well as Chairman of a subsidiary, SNBL U.S.A., Ltd., effective June 29, 2016. He joined the Company in April 1983. His previous titles include Chief Director of Global Business Development, President of Translational Research Company, Senior Managing Director and President of Preclinical Business Company. He used to serve as Chairman of the Board and Representative Director in a Japan-based subsidiary.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --